- President of Bioniche Food Safety an invited speaker -
BELLEVILLE, ON, Feb. 3 /PRNewswire-FirstCall/ - Bioniche Life Sciences Inc. (TSX: BNC), a research-based, technology-driven Canadian biopharmaceutical company, announced that its President of Bioniche Food Safety, Rick Culbert, is today participating in a Canadian Beef Value Chain Roundtable in Gatineau, Quebec. The two-day Roundtable involves representatives from regulatory authorities, ranchers, feedlot operators, processors, retail and food service representatives, feed suppliers and others. They are meeting to develop a strategy focused on improving competitiveness of the Canadian beef industry through market access and development, the regulatory environment, research and innovation and information transfer.
In his presentation to the Roundtable, Mr. Culbert will be sharing information about the Company's Econiche(TM) cattle vaccine, the world's first vaccine developed to reduce the shedding by cattle of Escherichia coli (E. coli) O157. Econiche is fully licensed for sale in Canada by the Canadian Food Inspection Agency (CFIA).
The vaccine has the potential to significantly reduce the amount of E. coli O157 shed into the environment by beef and dairy cattle and, in turn, reduce the risk to human health. An outbreak of human infection with E. coli O157 last fall in North Bay, Ontario, Canada involved 250 people reporting symptoms 50 lab-confirmed cases of human illness including one case of Haemolytic Uremic Syndrome (HUS). The illnesses were associated with a Harvey's Restaurant in that community.
Most strains of E. coli are harmless but some, like O157:H7, can cause severe illness and even be fatal when ingested by humans from contaminated meat, vegetables or water. Vaccination of cattle with Econiche can help reduce the risk of food and waterborne contamination with E. coli O157. Cows carry E. coli O157:H7 but they don't get sick. Where the disease comes from is people encountering contaminated food or water, usually from cow feces.
On-farm interventions to reduce the shedding of E. coli O157 by cattle, such as simple vaccination of cattle with Econiche, have the potential to reduce food and water contamination and the consequences associated with human infection with the deadly bacteria. Clinical trials conducted with Econiche have shown a significant reduction in the amount of E. coli shed in the manure of vaccinated cows.
"At today's Beef Value Chain Roundtable, I will be discussing the collaborative Canadian partnership that led to the development of Econiche," said Rick Culbert, President of Bioniche Food Safety. "I will also share information about the opportunity that vaccination of Canadian cattle represents beyond protecting public health, that is, a potential enhancement of the competitiveness of Canadian beef in export markets, where the vaccine is not yet available to producers."
About the Beef Value Chain Roundtable
The Beef Value Chain Roundtable was launched in January, 2003 and emerged as a key vehicle for helping ensure a coordinated response to Bovine Spongiform Encephalopathy (BSE) and as a key focal point for various working groups to engage with representatives of the entire beef value chain. Now more focused on long-term issues, membership on the beef roundtable includes ranchers, feedlot operators, processors, retail and food service representatives, feed suppliers and others.
About Bioniche Life Sciences Inc.
Bioniche Life Sciences Inc. is a research-based, technology-driven Canadian biopharmaceutical company focused on the discovery, development, manufacturing, and marketing of proprietary products for human and animal health markets worldwide. The fully-integrated company employs approximately 200 skilled personnel and has three operating divisions: Human Health, Animal Health, and Food Safety. The Company's primary goal is to develop proprietary cancer therapies supported by revenues from marketed products in human and animal health. Bioniche has been named one of the Top 50 Best Small and Medium-Sized Employers in Canada for 2009. For more information, please visit www.Bioniche.com.
Except for historical information, this news release may contain forward-looking statements that reflect the Company's current expectation regarding future events. These forward-looking statements involve risk and uncertainties, which may cause, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process, and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting.
|SOURCE Bioniche Life Sciences Inc.|
Copyright©2009 PR Newswire.
All rights reserved